Gartner, Eli Lilly, and The Trade Desk are among the top 10 large-cap losers last week (August 4–August 8). The declines were driven by weak financial results and guidance across key sectors. Ad-tech, cybersecurity, and AI hardware companies saw significant drops, with The Trade Desk (TTD) falling 37.87% after reporting second-quarter results and analysts lowering their price forecasts. Figma (FIG) dropped 21.88% amid continued volatility following its recent IPO. Gartner (IT) declined 30.82% after issuing soft full-year 2025 guidance. Fortinet (FTNT) slumped 23.95% after releasing disappointing second-quarter results, with analysts also downgrading its price target. Super Micro Computer (SMCI) fell 23.28% due to worse-than-expected fourth-quarter results, below-estimates for EPS, and a cut in FY26 sales guidance. Vertex Pharmaceuticals (VRTX) dropped 21.23% after its Vx-993 Phase 2 trial results and several analysts reducing their price forecasts. Twilio (TWLO) declined 19.58% after issuing third-quarter guidance below estimates. Snap (SNAP) fell 18.88% following the announcement of a $500 million notes offering. Eli Lilly (LLY) decreased 17.67% after reporting second-quarter results and sharing topline results from its Phase 3 ATTAIN-1 trial evaluating orforglipron in adults with obesity. Venture Global (VG) slumped 18.10% after receiving U.S. Department of Energy approval to increase Calcasieu Pass LNG capacity from 12.0 to 12.4 million tonnes per annum. The article asks readers if any of these stocks are part of their portfolio.

Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio?

Gartner, Eli Lilly, and The Trade Desk were among the top 10 large-cap stock losers during the week of August 4–8, 2025. The declines were attributed to weak financial results and disappointing guidance across sectors including ad-tech, cybersecurity, AI hardware, and pharmaceuticals. Key companies such as The Trade Desk, Figma, Gartner, Fortinet, Super Micro Computer, Vertex Pharmaceuticals, Twilio, Snap, and Venture Global all reported earnings or guidance that fell short of expectations, leading to significant price drops. Eli Lilly also saw a decline following its Phase 3 trial results. Venture Global received regulatory approval to expand its LNG capacity, though this did not offset its stock drop. The article prompts investors to assess whether any of these stocks are part of their portfolios.